title: A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan.
abstract: OBJECTIVE
  To compare insulin lispro Mix25 and human insulin 30/70 with regard to their effect on morning and evening postprandial glucose (PPG) control, and on average daily blood-glucose (BG), in patients with Type 2 diabetes who wish to fast during Ramadan.
  
  
  METHODS
  Insulin lispro Mix25 and human insulin 30/70 were compared in an open-label, multicenter, randomised, crossover study involving 151 patients. Each treatment period had a duration of 14 days during which the patients self-monitored their BG before and 2 h after the main meals on any 3 days within the last 5 days of each treatment period.
  
  
  RESULTS
  The 2 h PPG excursion following the main evening meal after sunset was significantly lower with insulin lispro Mix25 (3.4+/-2.9 mmol/l) compared with human insulin 30/70 (4.0+/-3.2 mmol/l, P=0.007). The evening pre-meal fasting BG values were also lower with insulin lispro Mix25 (7.1+/-2.2 mmol/l) versus human insulin 30/70 (7.5+/-2.6 mmol/l, P=0.034). The average daily BG concentration was 9.5+/-2.4 mmol/l during treatment with insulin lispro Mix25 versus 10.1+/-2.5 mmol/l with human insulin 30/70 given in identical doses (P=0.004).
  
  
  CONCLUSIONS
  When compared with human insulin 30/70, treatment of insulin-requiring Type 2 patients with insulin lispro Mix25 during Ramadan resulted in better average daily glycaemia, and better BG control before and after the evening meal. Insulin lispro Mix25 should be considered as a therapeutic option during Ramadan.
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: V
authors.initials: V
authors.lastname: Mattoo
authors.forename: Z
authors.initials: Z
authors.lastname: Milicevic
authors.forename: J K
authors.initials: JK
authors.lastname: Malone
authors.forename: M
authors.initials: M
authors.lastname: Schwarzenhofer
authors.forename: A
authors.initials: A
authors.lastname: Ekangaki
authors.forename: L K
authors.initials: LK
authors.lastname: Levitt
authors.forename: L H C
authors.initials: LH
authors.lastname: Liong
authors.forename: N
authors.initials: N
authors.lastname: Rais
authors.forename: H
authors.initials: H
authors.lastname: Tounsi
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005215:Fasting / Q000097:blood*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D061268:Insulin Lispro; D007514:Islam; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period / Q000187:drug effects / Q000502:physiology
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro